CClinicalTrials.gg
CompletedNCT00589147Updated May 28, 2012

A Prospective, Randomized, Controlled Study Comparing Three Tibial Component Designs in Total Knee Arthoplasty

An interventional study of The Zimmer NexGen Legacy Knee System, modular cemented tibia and The Zimmer NexGen Legacy Knee System, non-modular cemented tibia. in Total Knee Arthroplasty, sponsored by Mayo Clinic. Completed at 1 site in United States. Open to participants aged 20 Years to 85 Years. Per ClinicalTrials.gov, last updated 2012-05-28.

Sponsored by Mayo Clinic · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
397
Allocation
Randomized
Ages
20 Years to 85 Years
Sex
All
01

Study summary

SUMMARY A prospective, randomized, single-blinded clinical trial is proposed to compare three tibial tray designs for patients undergoing total knee arthroplasty. This study is designed to address the clinically important issues of tibial component modularity and fixation in total knee replacement. The Zimmer NexGen Legacy knee system is an FDA approved device and in this study will be used with 1) a modular tibial tray inserted with cement and 2) a non-modular tibial tray inserted with cement, and 3) a non-modular tibial tray inserted without cement. The insertion of total knee components without cement has been done clinically for over 20 years but has not been specifically approved by the FDA. Thus treatment arm 3, a non-modular tray inserted without cement, would involve the so-called off-label use of the device.

136 cases will be assigned to each arm of the study. Each patient will be assessed two months after surgery, one year after surgery, two years after surgery, five years after surgery, and every three to five years thereafter. The principal outcome measures will be the Knee Society Clinical rating scale, the SF-36 and the presence of significant lucent lines.. These measures will be compared among patients in the 3 trial arms at 5 years post surgery (or at the last follow-up point for those who drop out or become lost to follow-up). The Knee Society scores and SF-36 scores will be analyzed using analysis of variance models Rates of significant lucencies, perioperative mortality, as well as complications such as deep vein thrombosis, pulmonary embolus, neurovascular complication, and infection will be compared among the groups using chi-square tests . Rates of revision surgery will be compared among the groups using survivorship methods.

PURPOSE The primary aim of the study is to compare the results obtained with each of three tibial designs for patients undergoing total knee arthroplasty. Those results will be measured with disease-specific (Knee Society Scores), global (SF-36), and outcome measures. Radiographic results consisting of standing alignment, lateral and skyline views of the surgical knee will be recorded and analyzed. Completion of the intial investigation will occur at the 5-year interval after the last enrolled patient.

02

Conditions studied

  • Total Knee Arthroplasty
03

In context

Lead sponsor

Mayo Clinic is the lead sponsor of 3,218 studies on the registry; 669 are open to participants now.

Of its 445 completed or terminated interventional studies of FDA-regulated products, 313 (70%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients greater then or equal to 20 and less then or equal to 85 undergoing unilateral primary knee surgery for degenerative joint disease (DJD).

Exclusion criteria

Exclusion Criteria:

  • Age less than 20 years or > 85.
  • Severe deformity great then or equal to 20 degrees varus, valgus malalignment or flexion deformity.
  • Osteomyelitis, septicemia, prior infection of knee joint, or other active infections that may spread to other areas of the body.
  • The presence of infections, highly communicable diseases, e.g. AIDS, active tuberculosis, venereal disease, and hepatitis.
  • Significant neurological or musculoskeletal disorders or disease that may adversely affect normal gait or weight bearing.
  • Metastatic disease.
  • Any congenital, developmental, or other bone disease or previous knee surgery that may, in the surgeon's judgement, interfere with TK prosthesis survival or success, e.g. Paget's disease, Charcot's disease secondary to diabetes, severe osteoporosis, previous high tibial osteotomy, etc.
  • Presence of previous prosthetic knee replacement device (any type).
  • Arthrodesis of the affected knee.
  • Patients not requiring patella resurfacing.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
397 participants (actual)

Study arms

  • Active comparator
    1

    One study group will consist of patients treated with the modular cemented tibia.

    Device: The Zimmer NexGen Legacy Knee System, modular cemented tibia

  • Active comparator
    2

    Study arm will consist of patients that are treated with non-modular cemented tibia.

    Device: The Zimmer NexGen Legacy Knee System, non-modular cemented tibia.

  • Active comparator
    3

    Study arm will consist of patients that are treated with non-modular uncemented tibia.

    Device: The Zimmer NexGen Legacy Knee System, non-modular uncemented tibia

Interventions

  • DeviceThe Zimmer NexGen Legacy Knee System, modular cemented tibia

    modular cemented tibia

  • DeviceThe Zimmer NexGen Legacy Knee System, non-modular cemented tibia.

    non-modular cemented tibia.

  • DeviceThe Zimmer NexGen Legacy Knee System, non-modular uncemented tibia

    non-modular uncemented tibia

06

What researchers measure

Primary outcomes

  1. The primary aim of the study is to compare the results obtained with each of 3 tibial designs for patients undergoing TKA. Those results will be measured with disease-specific (Knee Society Scores), global (SF-36), and outcome measures.

    Time frame: 2 months, 1 year, 2 years, and 5 years

07

Study locations

1 site
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 28, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00589147
Lead sponsor
Mayo Clinic
Collaborators
Zimmer Biomet
First posted
Jan 9, 2008
Start date
Aug 2003
Primary completion
Jun 2007
Completion
Jun 2007
Last update
May 28, 2012

Study contacts

Mark W. Pagnano, MD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion